The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for ...
1don MSN
Metformin as a new standard of care to manage weight gain side effect of certain bipolar medications
Results from the largest and longest study of its kind have found that the drug metformin can help manage weight gain in ...
The FDA has approved Caplyta as adjunctive therapy with antidepressants to treat major depressive disorder in adults, ...
Millions of Americans with anxiety and depression struggle to find the right medication. The best fit may depend on your ...
Following a WESH 2 Investigates exclusive report on the death of a man behind bars at the Osceola County Jail, the man’s ...
A new study examining real-world hospital data reveals early indicators of who is most likely to benefit from Cobenfy, the ...
Each year, about 100,000 Americans experience psychosis, a serious condition that disrupts thoughts and perceptions so profoundly that it can distort a person's sense of reality.
Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...
Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...
A recent study of nearly 400,000 patients found that people with attention-deficit/hyperactivity disorder (ADHD) who take stimulants face a small but notable risk of ...
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best high volume stocks to buy according to Wall Street analysts. On October 10, the US FDA approved an expanded indication for UZEDY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback